Abstract

It is intended to provide a method of evaluating drug sensitivity, which comprises linking a gene polymorphism in the mu-opioid receptor gene or a haplotype composed of the gene polymorphisms to individual drug sensitivity; and an oligonucleotide selected from the group consisting of the nucleotide sequences represented by SEQ ID NOS: 1 to 98.